Are We Using the Right Pharmacological Tools to Target EphA4?

The EphA4 receptor has been proposed to be a key actor in neurodegenerative diseases. In the last years, several research groups focused their efforts on the discovery of small molecules capable of blocking EphA4 activity by binding its extracellular domain. However, none of the compounds so far identified possess adequate chemical and/or pharmacological profiles to assess the druggability of EphA4 in animal models. New efforts are required to deliver a new generation of suitable pharmacological tools.